Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
NCT ID: NCT03806179
Last Updated: 2023-12-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
7 participants
INTERVENTIONAL
2018-10-04
2022-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 MBq/kg Betalutin with rituximab treatment
10 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
10 MBq/kg Betalutin
10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
15 MBq/kg Betalutin with rituximab treatment
15 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
15 MBq/kg Betalutin
15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
10 MBq/kg Betalutin
10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
15 MBq/kg Betalutin
15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status of 0-2
* Histologically confirmed diagnosis (by 2008 World Health Organization \[WHO\] classification) of follicular lymphoma (grade 1, 2 or 3a)
* At least one (but not more than 3) prior regimens with an anti-CD20 antibody (alone or in combination with chemotherapy), with documented relapsed, refractory disease (must not be anti-CD20 antibody-refractory) or PD
* Presence of at least one bi-dimensionally measurable lesion by CT or MRI: longest diameter (LDi) \>1.5 cm for a nodal lesion; LDi \>1.0 cm for an extranodal lesion within 28 days prior to start of treatment
* Normal organ and bone marrow function defined as:
1. Absolute neutrophil count ≥1.5 x 109/L;
2. Platelet count ≥150 x 109/L;
3. Haemoglobin ≥9 g/dL;
4. Total bilirubin ≤1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome \[\<3.0 mg/dL\]);
5. Aspartate transaminase (AST); Alanine transaminase (ALT) or Alkaline phosphatase (ALP) ≤2.5 x ULN (or ≤5.0 x ULN if liver involvement by primary disease);
6. Adequate renal function as demonstrated by a serum creatinine within the upper limit of normal range
* Bone marrow involvement by lymphoma \<25%
* Life expectancy \>3 months
* Negative hepatitis B, hepatitis C and human immunodeficiency virus (HIV) screening tests
* Patients must agree to use effective contraception for 12 months following last study drug administration
Exclusion Criteria
* Evidence of histological transformation from FL to DLBCL at time of screening.
* Previous total body irradiation
* Chemotherapy, immunotherapy or investigational therapy within 28 days before the start of study drug administration (corticosteroid treatment at doses of ≤20 mg/day, topical or inhaled corticosteroids, granulocyte colony-stimulating factor \[G-CSF\] or granulocyte-macrophage colony-stimulating factor \[GM CSF\] are permitted up to 2 weeks prior to start of study treatment) or failure to recover from AEs associated with prior treatment
* Previous treatment with radioimmunotherapy
* Patients who are receiving any other investigational medicinal products
* Known or suspected central nervous system (CNS) involvement of lymphoma
* History of a previous treated cancer except for the following:
1. adequately treated local basal cell or squamous cell carcinoma of the skin
2. cervical carcinoma in situ
3. superficial bladder cancer or localised prostate cancer undergoing surveillance or surgery
4. localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy
5. other adequately treated Stage 1 or 2 cancer currently in CR
* Pregnant or lactating women
* Exposure to another CD37 targeting drug
* A known hypersensitivity to RTX, lilotomab, Betalutin or murine proteins or any excipient used in RTX, lilotomab or Betalutin
* Receipt of live, attenuated vaccine within 30 days prior to enrolment
* Evidence of severe or uncontrolled systemic diseases (e.g. ongoing infection, respiratory, cardiac, hepatic or psychiatric conditions) which in the Investigator's opinion would compromise the protocol objectives
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON Clinical Research
INDUSTRY
Nordic Nanovector
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Fosså, MD.PhD
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinika Hematoonkologie
Ostrava, Porubá, Czechia
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Repetto-Llamazares AHV, Malenge MM, O'Shea A, Eiriksdottir B, Stokke T, Larsen RH, Dahle J. Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma. Eur J Haematol. 2018 Oct;101(4):522-531. doi: 10.1111/ejh.13139. Epub 2018 Aug 31.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-004506-18
Identifier Type: OTHER
Identifier Source: secondary_id
LYMRIT -37-07(Archer-1)
Identifier Type: -
Identifier Source: org_study_id